Shruti Agrawal

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 7.9K citations · Full text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021 · 1.3K citations

Non-small-cell Lung Cancer, Medicine, Pharmacology +6

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam et al. · The Lancet Oncology · 2019 · 361 citations · Full text

Oncology, Four-year Survival, Immune Checkpoint Inhibitor +5

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

George D. Demetri, Patricia Lo Russo, Iain R. Macpherson et al. · Clinical Cancer Research · 2009 · 150 citations · Full text

Oncology, Cancer Therapeutics, Medicine +14

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

Feng Yan, Xiaoning Wang, Gaurav Bajaj et al. · Clinical Cancer Research · 2017 · 97 citations · Full text